{"id":"https://openalex.org/W4407302463","doi":"https://doi.org/10.1136/jitc-2024-010584","title":"TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial","display_name":"TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial","publication_year":2025,"publication_date":"2025-02-01","ids":{"openalex":"https://openalex.org/W4407302463","doi":"https://doi.org/10.1136/jitc-2024-010584","pmid":"https://pubmed.ncbi.nlm.nih.gov/39929671","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/11815413"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2024-010584","doi":"https://doi.org/10.1136/jitc-2024-010584","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2024-010584","pdf_url":"https://jitc.bmj.com/content/13/2/e010584.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for ImmunoTherapy of Cancer","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/13/2/e010584.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005436649","display_name":"Aung Naing","orcid":"https://orcid.org/0000-0002-4803-8513","observed_orcids":["https://orcid.org/0000-0002-4803-8513"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Aung Naing","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Centre, Houston, Texas, USA","The University of Texas MD Anderson Cancer Centre, Houston, Texas, USA anaing@mdanderson.org"],"raw_orcid":"https://orcid.org/0000-0002-4803-8513","affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Centre, Houston, Texas, USA","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Centre, Houston, Texas, USA anaing@mdanderson.org","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002575629","display_name":"Meredith Ann McKean","orcid":"https://orcid.org/0000-0003-0944-7418","observed_orcids":["https://orcid.org/0000-0003-0944-7418"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Meredith McKean","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, Tennessee, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee, USA","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060992997","display_name":"Anthony W. Tolcher","orcid":"https://orcid.org/0000-0002-6322-9721","observed_orcids":["https://orcid.org/0000-0002-6322-9721"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anthony Tolcher","raw_affiliation_strings":["NEXT Oncology and Texas Oncology, San Antonio, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NEXT Oncology and Texas Oncology, San Antonio, Texas, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059699000","display_name":"Anja Victor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Anja Victor","raw_affiliation_strings":["Merck Healthcare KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Healthcare KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014360658","display_name":"Ping Hu","orcid":"https://orcid.org/0000-0002-5779-5743","observed_orcids":["https://orcid.org/0000-0002-5779-5743"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ping Hu","raw_affiliation_strings":["EMD Serono, Billerica, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono, Billerica, Massachusetts, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062273729","display_name":"Wei Gao","orcid":"https://orcid.org/0009-0004-3149-8486","observed_orcids":["https://orcid.org/0009-0004-3149-8486","https://orcid.org/0009-0000-8029-5483"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wei Gao","raw_affiliation_strings":["EMD Serono, Billerica, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono, Billerica, Massachusetts, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058447324","display_name":"Marco Antonio Ferraz Nogueira Filho","orcid":"https://orcid.org/0000-0002-8290-1114","observed_orcids":["https://orcid.org/0000-0002-8290-1114"]},"institutions":[{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Marco A F Nogueira Filho","raw_affiliation_strings":["Merck Healthcare KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Healthcare KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069434178","display_name":"Thomas Kitzing","orcid":"https://orcid.org/0000-0003-3424-4882","observed_orcids":["https://orcid.org/0000-0003-3424-4882"]},"institutions":[{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Thomas Kitzing","raw_affiliation_strings":["Merck Healthcare KGaA, Darmstadt, Germany"],"raw_orcid":"https://orcid.org/0000-0003-3424-4882","affiliations":[{"raw_affiliation_string":"Merck Healthcare KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080701119","display_name":"Stephan Gleicher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Stephan Gleicher","raw_affiliation_strings":["Merck Healthcare KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Healthcare KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Daniel Holland","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Daniel Holland","raw_affiliation_strings":["Merck Healthcare KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Healthcare KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031538047","display_name":"Emilia Richter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Emilia Richter","raw_affiliation_strings":["Merck Healthcare KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Healthcare KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051243384","display_name":"Keyvan Tadjalli Mehr","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Keyvan Tadjalli-Mehr","raw_affiliation_strings":["Merck Healthcare KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Healthcare KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I4405266695"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000204204","display_name":"Lillian L. Siu","orcid":"https://orcid.org/0000-0002-3500-0540","observed_orcids":["https://orcid.org/0000-0002-3500-0540"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Lillian L Siu","raw_affiliation_strings":["Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada","institution_ids":["https://openalex.org/I2802654988"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5005436649"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":4.4987,"has_fulltext":true,"cited_by_count":11,"citation_normalized_percentile":{"value":0.95550162,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":99},"biblio":{"volume":"13","issue":"2","first_page":"e010584","last_page":"e010584"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tigit","display_name":"TIGIT","score":0.621999979019165},{"id":"https://openalex.org/keywords/bintrafusp-alfa","display_name":"bintrafusp alfa","score":0.9679999947547913},{"id":"https://openalex.org/keywords/anti-tigit-antibody","display_name":"anti-TIGIT antibody","score":0.7649999856948853},{"id":"https://openalex.org/keywords/tgf-beta-inhibition","display_name":"TGF-beta inhibition","score":0.6119999885559082},{"id":"https://openalex.org/keywords/pd-1-pd-l1-blockade","display_name":"PD-1/PD-L1 blockade","score":0.8410000205039978},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.7400000095367432},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.7080000042915344},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7910000085830688},{"id":"https://openalex.org/keywords/adrenal-insufficiency","display_name":"adrenal insufficiency","score":0.9800000190734863},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.7570000290870667},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8679999709129333},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9589999914169312},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8709999918937683},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.703000009059906}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.782940685749054},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.706305742263794},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6842530965805054},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6178842186927795},{"id":"https://openalex.org/C2779118045","wikidata":"https://www.wikidata.org/wiki/Q21114021","display_name":"TIGIT","level":4,"score":0.5926744341850281},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5019371509552002},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4839232563972473},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.4489285349845886},{"id":"https://openalex.org/C2778594517","wikidata":"https://www.wikidata.org/wiki/Q2260058","display_name":"Chills","level":2,"score":0.43759772181510925},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4350378215312958},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4323039650917053},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35455089807510376},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.257110595703125},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2568128705024719},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.2471858561038971},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.23228448629379272},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.20451006293296814}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D011971","descriptor_name":"Receptors, Immunologic","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1136/jitc-2024-010584","doi":"https://doi.org/10.1136/jitc-2024-010584","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2024-010584","pdf_url":"https://jitc.bmj.com/content/13/2/e010584.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for ImmunoTherapy of Cancer","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:11815413","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11815413","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11815413/pdf/jitc-13-2.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Immunother Cancer","raw_type":"Text"},{"id":"pmid:39929671","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39929671","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for immunotherapy of cancer","raw_type":"Journal Article"},{"id":"pmh:oai:digitalcommons.library.tmc.edu:uthgsbs_docs-5738","doi":null,"is_oa":false,"landing_page_url":"https://digitalcommons.library.tmc.edu/uthgsbs_docs/4877","pdf_url":null,"source":{"id":"https://openalex.org/S4377196655","display_name":"Digital Commons-TMC (Texas Medical Center)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1337852284","host_organization_name":"Texas Medical Center","host_organization_lineage":["https://openalex.org/I1337852284"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Faculty, Staff and Student Publications","raw_type":"text"},{"id":"pmh:oai:doaj.org/article:2bc752abb112475586885707089bcbde","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/2bc752abb112475586885707089bcbde","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 13, Iss 2 (2025)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2024-010584","doi":"https://doi.org/10.1136/jitc-2024-010584","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2024-010584","pdf_url":"https://jitc.bmj.com/content/13/2/e010584.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for ImmunoTherapy of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G950686094","display_name":null,"funder_award_id":"CrossRef Funder ID: 10.13039/100009945","funder_id":"https://openalex.org/F375939012","funder_display_name":"Merck Healthcare KGaA"}],"funders":[{"id":"https://openalex.org/F375939012","display_name":"Merck Healthcare KGaA","ror":"https://ror.org/04vpzfb52"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4407302463.pdf","grobid_xml":"https://content.openalex.org/works/W4407302463.grobid-xml"},"referenced_works_count":29,"referenced_works":["https://openalex.org/W1481317976","https://openalex.org/W1987165863","https://openalex.org/W2029399624","https://openalex.org/W2042990006","https://openalex.org/W2139494088","https://openalex.org/W2142169541","https://openalex.org/W2330814896","https://openalex.org/W2534828940","https://openalex.org/W2892047621","https://openalex.org/W2895507049","https://openalex.org/W2898886694","https://openalex.org/W2909132011","https://openalex.org/W2995440672","https://openalex.org/W3081994625","https://openalex.org/W3094444934","https://openalex.org/W3102804765","https://openalex.org/W3149714833","https://openalex.org/W3193127644","https://openalex.org/W3212804507","https://openalex.org/W3215437584","https://openalex.org/W4282931684","https://openalex.org/W4312194555","https://openalex.org/W4312944759","https://openalex.org/W4327545673","https://openalex.org/W4379791505","https://openalex.org/W4386466678","https://openalex.org/W4387115048","https://openalex.org/W4387784526","https://openalex.org/W4388733486"],"related_works":["https://openalex.org/W4393985505","https://openalex.org/W4295819095","https://openalex.org/W3212620754","https://openalex.org/W4282931684","https://openalex.org/W3018513447","https://openalex.org/W3124882043","https://openalex.org/W2999614627","https://openalex.org/W2796502862","https://openalex.org/W7223340075","https://openalex.org/W3203415203"],"abstract_inverted_index":{"BACKGROUND:":[0],"M6223":[1,58,63,70,83,131,143,227,256],"is":[2,26,257],"an":[3],"intravenous":[4],"(IV),":[5],"Fc-competent,":[6],"fully":[7],"human,":[8],"antagonistic,":[9],"anti-T":[10],"cell":[11],"immunoreceptor":[12,16],"with":[13,47,78,86,244,261,268],"immunoglobulin":[14],"and":[15,37,104,115,137,157,166,184,191,209,229,250],"tyrosine-based":[17],"inhibitory":[18],"motif":[19],"domains":[20],"(TIGIT)":[21],"antibody.":[22],"Bintrafusp":[23],"alfa":[24],"(BA)":[25],"a":[27,196,240],"bifunctional":[28],"fusion":[29],"protein":[30],"that":[31],"simultaneously":[32],"blocks":[33],"nonredundant":[34],"immunosuppressive":[35],"TGF-\u03b2":[36],"PD-(L)1":[38],"pathways.":[39],"METHODS:":[40],"This":[41],"first-in-human,":[42],"dose-escalation":[43],"study":[44],"in":[45,181,188,206,210,259,266],"patients":[46,187,267],"advanced":[48,269],"solid":[49],"tumors":[50],"(N=58;":[51],"aged":[52],"\u226518":[53],"years,":[54],"ECOG":[55],"PS\u22641)":[56],"evaluated":[57],"alone":[59],"(Part":[60,80,129,141],"1A,":[61],"n=40;":[62],"10-2400":[64],"mg":[65,72,85,133,216,222,231],"every":[66,73,91,134,217,223,232],"2":[67,92,135,218,233],"weeks,":[68,75,93],"n=32;":[69],"2400":[71,221],"3":[74,126,139,224],"n=8)":[76],"or":[77,220],"BA":[79,87,147],"1B,":[81,192],"n=18;":[82],"300-1600":[84],"1200":[88],"mg;":[89],"both":[90,248],"intravenous).":[94],"Primary":[95],"objectives":[96,111],"were":[97,123,160,204,214],"safety,":[98],"tolerability,":[99],"maximum":[100],"tolerated":[101],"dose":[102,106],"(MTD)":[103],"recommended":[105],"for":[107,226,235,247],"expansion":[108],"(RDE).":[109],"Additional":[110],"included":[112],"pharmacokinetics,":[113],"pharmacodynamics":[114],"clinical":[116],"activity":[117],"(NCT04457778).":[118],"RESULTS:":[119],"Two":[120],"dose-limiting":[121],"toxicities":[122],"observed:":[124],"grade":[125,138],"adrenal":[127],"insufficiency":[128],"1A:":[130],"900":[132],"weeks)":[136],"anemia":[140],"1B:":[142],"300":[144],"mg,":[145],"only":[146],"related).":[148],"MTD":[149],"was":[150,179],"not":[151],"reached.":[152],"Overall,":[153],"median":[154],"overall":[155],"survival":[156,159],"progression-free":[158],"7.6":[161],"(95%":[162,168],"CI":[163,169],"4.9,":[164],"12.0)":[165],"1.4":[167],"1.3,":[170],"1.8)":[171],"months,":[172],"respectively.":[173,193],"Stable":[174],"disease":[175],"as":[176],"best":[177],"response":[178],"observed":[180,205],"13":[182],"(32.5%)":[183],"5":[185],"(27.8%)":[186],"parts":[189],"1A":[190],"M6223\u00b1BA":[194,238],"displayed":[195],"linear":[197],"pharmacokinetic":[198],"profile.":[199],"Anti-TIGIT":[200],"mode-of-action-related":[201],"pharmacodynamic":[202],"effects":[203],"peripheral":[207],"blood":[208],"tumor":[211],"tissue.":[212],"RDEs":[213,245],"1600":[215],"weeks":[219,225,234],"monotherapy":[228,249],"1600+1200":[230],"M6223+BA.":[236],"CONCLUSIONS:":[237],"had":[239],"manageable":[241],"safety":[242],"profile,":[243],"defined":[246],"combination":[251,260],"therapy.":[252],"Further":[253],"evaluation":[254],"of":[255],"ongoing":[258],"the":[262],"PD-L1":[263],"inhibitor":[264],"avelumab":[265],"urothelial":[270],"carcinoma":[271],"(JAVELIN":[272],"Bladder":[273],"Medley;":[274],"NCT05327530).":[275],"TRIAL":[276],"REGISTRATION":[277],"NUMBER:":[278],"NCT04457778.":[279]},"counts_by_year":[{"year":2026,"cited_by_count":8},{"year":2025,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2025-02-10T00:00:00"}